Co-silencing of Birc5 (survivin) and Hspa5 (Grp78) induces apoptosis in hepatoma cells more efficiently than single gene interference

Wang,Qiang; Shu,Rong; He,Huijun; Wang,Li; Ma,Yuan; Zhu,Huifen; Wang,Zhihua; Wang,Shuo; Shen,Guanxin; Lei,Ping

doi:10.3892/ijo.2012.1471

Co-silencing of Birc5 (survivin) and Hspa5 (Grp78) induces apoptosis in hepatoma cells more efficiently than single gene interference

Authors:
- Qiang Wang
- Rong Shu
- Huijun He
- Li Wang
- Yuan Ma
- Huifen Zhu
- Zhihua Wang
- Shuo Wang
- Guanxin Shen
- Ping Lei
View Affiliations

Affiliations: Department of Immunology, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, P.R. China, Department of Anesthesiology, Hu Bei Zhong Shan Hospital, Wuhan, Hubei, P.R. China, Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, P.R. China, Lady Davis Institute, McGill University, Sir Mortimer B. Davis-Jewish General Hospital, Montreal, QC, Canada
Published online on: May 10, 2012 https://doi.org/10.3892/ijo.2012.1471
Pages: 652-660

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Birc5 (previously known as survivin) is a cancer-specific protein. Due to the upregulation of its expression in various human malignancies and its key role in apoptosis, proliferation and angiogenesis, Birc5 has attracted attention as a target for anticancer therapies. In this study, when Birc5 was silenced in HepG2 cells, 29.7±3.3% cells underwent apoptosis as expected. It was found that the expression levels of glucose-regulated protein 78 (Hspa5, previously known as Grp78) was increased by almost 3-fold in Birc5-silenced HepG2 cells. Hspa5, a master regulator of the anti-apoptotic unfolded protein response signalling network, can also promote tumor proliferation, survival and metastasis. Hence, we hypothesized that the co-silencing of Birc5 and Hspa5 may exert a stronger apoptosis-inducing effect than single gene interference. To verify this, the expression levels of Birc5 and Hspa5 in human hepatocellular carcinoma tissues were determined. Immunohistochemical staining showed that the expression of Birc5 and Hspa5 was elevated in 28 out of 31 samples. Additionally, plasmid-based siRNA against Birc5 and/or Hspa5 were constructed and transfected into the human hepatocellular liver carcinoma cell line, HepG2. Compared with the HepG2 cells, in which Birc5 or Hspa5 were silenced alone, only 44.2±3.4% of the co-silenced cells proliferated, and 40.3±3.7% co-silenced cells underwent apoptosis (p<0.05). Furthermore, tumor formation from inoculated subcutaneous co-silenced cells in nude mice was inhibited significantly. The current study suggests that Birc5 and Hspa5 could be important survival factors for hepatoma carcinoma cells and that the simultaneous knockdown of Birc5 and Hspa5 is more effective in inducing apoptosis in HepG2 cells than the knockdown of Birc5 or Hspa5 alone. The co-silencing of Birc5 and Hspa5 could be warranted for cancer therapy.

View Figures

View References

1	Altieri DC: Survivin, versatile modulation of cell division and apoptosis in cancer. Oncogene. 22:8581–8589. 2003. View Article : Google Scholar : PubMed/NCBI
2	Chawla-Sarkar M, Bae SI, Reu FJ, et al: Downregulation of Bcl-2, FLIP or IAPs (XIAP and survivin) by siRNAs sensitizes resistant melanoma cells to Apo2L/TRAIL-induced apoptosis. Cell Death Differ. 11:915–923. 2004. View Article : Google Scholar : PubMed/NCBI
3	Nomura T, Yamasaki M, Nomura Y and Mimata H: Expression of the inhibitors of apoptosis proteins in cisplatin-resistant prostate cancer cells. Oncol Rep. 14:993–997. 2005.PubMed/NCBI
4	Li F, Yang J, Ramnath N, Javle MM and Tan D: Nuclear or cytoplasmic expression of survivin: what is the significance? Int J Cancer. 114:509–512. 2005. View Article : Google Scholar : PubMed/NCBI
5	Hinnis AR, Luckett JC and Walker RA: Survivin is an independent predictor of short-term survival in poor prognostic breast cancer patients. Br J Cancer. 96:639–645. 2007. View Article : Google Scholar : PubMed/NCBI
6	Altieri DC: Validating survivin as a cancer therapeutic target. Nat Rev Cancer. 3:46–54. 2003. View Article : Google Scholar : PubMed/NCBI
7	Olie RA, Simoes-Wust AP, Baumann B, et al: A novel antisense oligonucleotide targeting survivin expression induces apoptosis and sensitizes lung cancer cells to chemotherapy. Cancer Res. 60:2805–2809. 2000.
8	Pennati M, Binda M, Colella G, et al: Ribozyme-mediated inhibition of survivin expression increases spontaneous and drug-induced apoptosis and decreases the tumorigenic potential of human prostate cancer cells. Oncogene. 23:386–394. 2004. View Article : Google Scholar
9	Liu H, Guo S, Roll R, et al: Phi29 pRNA vector for efficient escort of hammerhead ribozyme targeting survivin in multiple cancer cells. Cancer Biol Ther. 6:697–704. 2007. View Article : Google Scholar : PubMed/NCBI
10	Li L, Liu J, Diao Z, et al: Evaluation of specific delivery of chimeric phi29 pRNA/siRNA nanoparticles to multiple tumor cells. Mol Biosyst. 5:1361–1368. 2009. View Article : Google Scholar : PubMed/NCBI
11	Pennati M, Folini M and Zaffaroni N: Targeting survivin in cancer therapy: fulfilled promises and open questions. Carcinogenesis. 28:1133–1139. 2007. View Article : Google Scholar : PubMed/NCBI
12	Gyurkocza B, Plescia J, Raskett CM, et al: Antileukemic activity of shepherdin and molecular diversity of hsp90 inhibitors. J Natl Cancer Inst. 98:1068–1077. 2006. View Article : Google Scholar : PubMed/NCBI
13	Fortugno P, Beltrami E, Plescia J, et al: Regulation of survivin function by Hsp90. Proc Natl Acad Sci USA. 100:13791–13796. 2003. View Article : Google Scholar : PubMed/NCBI
14	Cheung CH, Chen HH, Cheng LT, et al: Targeting Hsp90 with small molecule inhibitors induces the over-expression of the anti-apoptotic molecule, survivin, in human A549, HONE-1 and HT-29 cancer cells. Mol Cancer. 9:772010. View Article : Google Scholar : PubMed/NCBI
15	Tanimoto R, Sakaguchi M, Abarzua F, et al: Down-regulation of BiP/GRP78 sensitizes resistant prostate cancer cells to gene-therapeutic overexpression of REIC/Dkk3. Int J Cancer. 126:1562–1569. 2010.PubMed/NCBI
16	Schardt JA, Weber D, Eyholzer M, Mueller BU and Pabst T: Activation of the unfolded protein response is associated with favorable prognosis in acute myeloid leukemia. Clin Cancer Res. 15:3834–3841. 2009. View Article : Google Scholar : PubMed/NCBI
17	Wang Q, He Z, Zhang J, et al: Overexpression of endoplasmic reticulum molecular chaperone GRP94 and GRP78 in human lung cancer tissues and its significance. Cancer Detect Prev. 29:544–551. 2005. View Article : Google Scholar : PubMed/NCBI
18	Arnaudeau S, Arboit P, Bischof P, et al: Glucose-regulated protein 78: a new partner of p53 in trophoblast. Proteomics. 9:5316–5327. 2009. View Article : Google Scholar : PubMed/NCBI
19	Huang WJ, Xia LM, Zhu F, et al: Transcriptional upregulation of HSP70-2 by HIF-1 in cancer cells in response to hypoxia. Int J Cancer. 124:298–305. 2009. View Article : Google Scholar : PubMed/NCBI
20	Wang M, Zhao XR, Wang P, et al: Glucose regulated proteins 78 protects insulinoma cells (NIT-1) from death induced by streptozotocin, cytokines or cytotoxic T lymphocytes. Int J Biochem Cell Biol. 39:2076–2082. 2007. View Article : Google Scholar : PubMed/NCBI
21	Wang M, Wang P, Peng JL, et al: The altered expression of glucose-regulated proteins 78 in different phase of streptozotocin-affected pancreatic beta-cells. Cell Stress Chaperones. 14:43–48. 2009. View Article : Google Scholar : PubMed/NCBI
22	Carrasco RA, Stamm NB, Marcusson EG, et al: Antisense inhibition of survivin expression as a cancer therapeutic. Mol Cancer Ther. 10:221–232. 2011. View Article : Google Scholar : PubMed/NCBI
23	Sapra P, Wang M, Bandaru R, et al: Down-modulation of survivin expression and inhibition of tumor growth in vivo by EZN-3042, a locked nucleic acid antisense oligonucleotide. Nucleosides Nucleotides Nucleic Acids. 29:97–112. 2010. View Article : Google Scholar : PubMed/NCBI
24	Nakahara T, Kita A, Yamanaka K, et al: Broad spectrum and potent antitumor activities of YM155, a novel small-molecule surviving suppressant, in a wide variety of human cancer cell lines and xenograft models. Cancer Sci. 102:614–621. 2011. View Article : Google Scholar
25	Nakahara T, Takeuchi M, Kinoyama I, et al: YM155, a novel small-molecule survivin suppressant, induces regression of established human hormone-refractory prostate tumor xenografts. Cancer Res. 67:8014–8021. 2007. View Article : Google Scholar
26	Ashihara E, Kawata E and Maekawa T: Future prospect of RNA interference for cancer therapies. Curr Drug Targets. 11:345–360. 2010. View Article : Google Scholar : PubMed/NCBI
27	Tirrò E, Consoli ML, Massimino M, et al: Altered expression of c-IAP1, survivin, and Smac contributes to chemotherapy resistance in thyroid cancer cells. Cancer Res. 66:4263–4272. 2006.PubMed/NCBI
28	Kappler M, Bache M, Bartel F, et al: Knockdown of survivin expression by small interfering RNA reduces the clonogenic survival of human sarcoma cell lines independently of p53. Cancer Gene Ther. 11:186–193. 2004. View Article : Google Scholar : PubMed/NCBI
29	Wu YF, Liang XJ, Liu YY, et al: Antisense oligonucleotide targeting survivin inhibits growth by inducing apoptosis in human osteosarcoma cells MG-63. Neoplasma. 57:501–506. 2010. View Article : Google Scholar : PubMed/NCBI
30	Xia C, Xu Z, Yuan X, et al: Induction of apoptosis in mesothelioma cells by antisurvivin oligonucleotides. Mol Cancer Ther. 1:687–694. 2002.PubMed/NCBI
31	Hendruschk S, Wiedemuth R, Aigner A, et al: RNA interference targeting survivin exerts antitumoral effects in vitro and in established glioma xenografts in vivo. Neuro Oncol. 13:1074–1089. 2011. View Article : Google Scholar : PubMed/NCBI
32	Kern J, Untergasser G, Zenzmaier C, et al: GRP-78 secreted by tumor cells blocks the antiangiogenic activity of bortezomib. Blood. 114:3960–3967. 2009. View Article : Google Scholar : PubMed/NCBI
33	Reddy RK, Mao C, Baumeister P, et al: Endoplasmic reticulum chaperone protein GRP78 protects cells from apoptosis induced by topoisomerase inhibitors: role of ATP binding site in suppression of caspase-7 activation. J Biol Chem. 278:20915–20924. 2003. View Article : Google Scholar
34	Li J and Lee AS: Stress induction of GRP78/BiP and its role in cancer. Curr Mol Med. 6:45–54. 2006. View Article : Google Scholar : PubMed/NCBI
35	Saito S and Tomida A: Use of chemical genomics in assessment of the UPR. Methods Enzymol. 491:327–341. 2011. View Article : Google Scholar : PubMed/NCBI
36	Ni M, Zhou H, Wey S, et al: Regulation of PERK signaling and leukemic cell survival by a novel cytosolic isoform of the UPR regulator GRP78/BiP. PLoS One. 4:e68682009. View Article : Google Scholar : PubMed/NCBI